Editorial: Epidemic-Assistance Investigations by the Centers for Disease Control and Prevention—The First 60 Years

door O'Brien, Thomas R.
Gepubliceerd in 2011

What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?

door O'Brien, Thomas R., Jackson, Sarah S.
Gepubliceerd in J Interferon Cytokine Res (2019)

Recent Decline in Hepatocellular Carcinoma Rates in the United States

door Shiels, Meredith S., O’Brien, Thomas R.
Gepubliceerd in Gastroenterology (2020)

IL28B-Genotype Testing Now and in the Era of Direct-Acting Antiviral Agents

door Morgan, Timothy R., O’Brien, Thomas R.
Gepubliceerd in 2010

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

door O’Brien, Thomas R., Pfeiffer, Ruth M.
Gepubliceerd in Open Forum Infect Dis (2015)

Population Genetics and Comparative Genetics of CLDN1, a Gene Involved in Hepatitis C Virus Entry

door Bekker, Vincent, O’Brien, Thomas R., Chanock, Stephen
Gepubliceerd in 2009

The role of genetics in hepatic fibrosis amongst HCV patients

door Park, Heiyoung, O’Brien, Thomas R., Rehermann, Barbara
Gepubliceerd in Hepatology (2018)

Possible Role of Hepatitis D Virus in Severe Hepatitis Related to Hepatitis B Virus Reactivation After Therapy for Chronic Hepatitis C

door Mahale, Parag, Glenn, Jeffrey S., O’Brien, Thomas R.
Gepubliceerd in Ann Intern Med (2017)

Interferon-lambda and therapy for chronic hepatitis C virus infection

door Donnelly, Raymond P., Dickensheets, Harold, O'Brien, Thomas R.
Gepubliceerd in 2011

What makes the hepatitis C virus evolve?

door O'Brien, Thomas R, Hartmann, Rune, Prokunina-Olsson, Ludmila
Gepubliceerd in eLife (2019)

IFNL4 Genotype is Associated with Virologic Relapse After 8-Week Treatment with Sofosbuvir, Velpatasvir and Voxilaprevir

door O’Brien, Thomas R., Kottilil, Shyam, Pfeiffer, Ruth M.
Gepubliceerd in Gastroenterology (2017)

IFN-λ4: The Paradoxical New Member of the Interferon Lambda Family

door O'Brien, Thomas R., Prokunina-Olsson, Ludmila, Donnelly, Raymond P.
Gepubliceerd in 2014

Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention

door Koshiol, Jill, Liu, Zhiwei, O’Brien, Thomas R., Hildesheim, Allan
Gepubliceerd in Cancer Epidemiol (2018)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

door O'Brien, Thomas R., Lang Kuhs, Krystle A., Pfeiffer, Ruth M.
Gepubliceerd in Open Forum Infect Dis (2014)

Lymphocyte subsets in hemophilic patients with hepatitis C virus infection with or without human immunodeficiency virus co-infection: a nested cross-sectional study

door Zhang, Mingdong, O'Brien, Thomas R, Kopp, William C, Goedert, James J
Gepubliceerd in 2005

Re: Pearlman and Ehleben - Hepatitis C Genotype 1 Virus with Low Viral Load and Rapid Virologic Response to Peginterferon/Ribavirin Obviates a Protease Inhibitor

door Wang, Alan S., Pfeiffer, Ruth M., Morgan, Timothy R., O'Brien, Thomas R.
Gepubliceerd in 2014

No Scientific Basis to Restrict 8 Weeks of Treatment with Ledipasvir/Sofosbuvir to Patients with HCV RNA <6,000,000 IU/ml

door O’Brien, Thomas R., Feld, Jordan J., Kottilil, Shyam, Pfeiffer, Ruth M.
Gepubliceerd in Hepatology (2015)

Shortening the duration of therapy for chronic hepatitis C infection

door Emmanuel, Benjamin, Wilson, Eleanor M, O’Brien, Thomas R, Kottilil, Shyam, Lau, George
Gepubliceerd in Lancet Gastroenterol Hepatol (2017)

Meeting Overview: Interferon Lambda—Disease Impact and Therapeutic Potential

door O'Brien, Thomas R., Young, Howard A., Donnelly, Raymond P., Prokunina-Olsson, Ludmila
Gepubliceerd in J Interferon Cytokine Res (2019)

Race or Genetic Makeup for HCV Treatment Decisions?

door O’Brien, Thomas R., Kottilil, Shyam, Feld, Jordan J., Morgan, Timothy R., Pfeiffer, Ruth M.
Gepubliceerd in Hepatology (2017)